Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease

European Journal of Haematology

Volumn 64, Issue 2, 2000, Pages 80-84

  Aviram, A ^a   Rabizadeh, E ^a   Zimra, Y ^a   Yeshoron, M ^a   Marmelstein, M ^a   Shaklai, M ^a   Bairey, O ^a  

^a Beilinson Campus   (United States)

Author keywords

B CLL; Bax; Bcl 2; Disease stage

Indexed keywords

BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; ETOPOSIDE; FLUDARABINE; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKOCYTE COUNT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; FEMALE; HUMANS; IMMUNOBLOTTING; LEUKEMIA, B-CELL, CHRONIC; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0034071909     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90042.x     Document Type: Article

References (20)

1. 1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1056.
2. 2. Caligaris-Cappio F, Gottardi D, Alfarano A, Stacchini A, Gregoretti MG, Ghia P, Bertero MT, Novarino A, Bergui L. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 1993;19:601-613.
3. 3. Tsujimoto Y, Gorham J, Cossman J, Jasffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-1393.
4. 4. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K. Recent progress in chronic lymphocytic leukemia. Leukemia 1994;8:1610-1614.
5. 5. Reed JC. Double identity for proteins of the bcl-2 family. Nature 1997;387:773-776.
6. 6. Schendel SL, Xie Z, Montal MO, et al. Channel formation by antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 1997;94:5113-5118.
7. 7. Yang E, Korsmeyer SJ. Molecular apoptosis: A disourse on the bcl-2 family and cell death. Blood 1996;88:386-401.
8. 8. Farrow SN, Brown R. New members of the bcl-2 family and their protein partners. Curr Opin Genet Develop 1996;6:45-49.
9. 9. Thomas A, El Rouby S, Reed JC, Krajeewski S, Silber R, Potmesil M, Newcomb EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
10. 10. Oltvai Z, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-619.
11. 11. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Porton G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
12. 12. Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of bcl-2 protein increases the half-life of p21Bax. J Biol Chem 1992;270:26,049-26,052.
13. 13. Agular-Santelises M, Rottenberg ME, Lewine N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996;69:114-119.
14. 14. Robertson LE, Plunket W, McConnel K, Keating MJ, McDonnell TJ. Leukemia 1996;10:456-459.
15. 15. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlation with in vitro and in vivo chemoresponses. Blood 1998;91:3379-3389.
16. 16. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukemia. Br J Haematol 1996;95: 513-517.
17. 17. Cotter FE. Antisense therapy for lymphomas. Hematol Oncol 1997;15:3-11.
18. 18. Webb A, Cunningham D, Cotter EF, Clarke PA, Di Stefano F, Ross P, Corbo M, Dziewanowska Z. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349:1137-1141.
19. 19. Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabreta B, Zupi G. C-myc antisense oligonucleotides enhances the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998;58:283-289.
20. 20. Campble MJ, Dawson M, Koeffler HP. Growth inhibition of DU-145 prostate cancer cells by bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) alltrans retinamide. Br J Cancer 1998;77:739-744.